Alvotech AI Stock Analysis
Alvotech (Z45) AI Stock Analysis
Alvotech
(Frankfurt:Z45)
No summary available
Alvotech (Z45) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.56B
- Dividend Yield
- ―
- Average Volume (3M)
- 1,349
- Price to Earnings (P/E)
- -5.7
- Beta (1Y)
- 0.58
- Revenue Growth
- -18.66%
- EPS Growth
- -399.21%
- Country
- Germany
- Employees
- 1,279
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Alvotech Business Overview & Revenue Model
Company Description
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone dise...
Alvotech Earnings Call Summary
The call was predominantly positive, with strong Q3 product revenue and EBITDA growth, improving manufacturing capacity and productivity, multiple regulatory milestones, expanding commercial reach, strong stated demand, and expectations for Q4 recovery and 2027 deleveraging. These positives were tempered by a 23% nine-month revenue decline, ongoing supply ramp-up, cash use and high interest payments, a full-year outlook trending toward the lower end of guidance, compressed 2026 product margins, and patent-related launch uncertainty.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the full year, Alvotech targets revenues in the range of $650 million to $700 million and Adjusted EBITDA in the range of $180 to $220 million, expects a significant proportion of full year revenue and EBITDA to be generated in the fourth quarter, expects the fourth quarter to be the strongest quarter of the year and the strongest in Alvotech history, and now expects performance to trend towards the lower end of our stated range; the company expects to deliver year on-year growth in 2026, cash flow positive in Q4 of 26, healthy deleveraging towards the later half of 2027, and substantial improvements on the upside between 26 in 2027, while 2027 guidance has not been provided, total R&D spend remains in the area of 200 million with 50% capitalized, product margins are expected to remain somewhat compressed through 2026 and have a stronger product margin profile as we enter into 2027, and interest payments are expected to remain around this level until deleveraging, which is somewhere in 2027.
Alvotech Risk Analysis
Alvotech disclosed 95 risk factors in its most recent earnings report. Alvotech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAlvotech Peers Comparison
Overall Rating
TAK67Neutral
VTRS67Neutral
RDY66Neutral
AMRX58Neutral
HCM49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | $68.79B | 28.18 | 5.07% | 3.32% | 0.67% | -12.01% | |
| 67Neutral | $23.25B | -38.26 | -4.24% | 2.37% | 4.80% | 82.97% | |
| 66Neutral | $12.38B | 41.61 | 7.37% | 0.56% | -10.52% | -55.45% | |
| 58Neutral | $7.36B | 50.88 | 131.71% | ― | 8.88% | 2272.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $2.41B | 149.52 | 1.43% | ― | -8.81% | -96.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:Z45 | Alvotech | 3.96 | -0.52 | -11.61% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.98 | 1.16 | 8.36% | |
| VTRS | Viatris, Inc. | 20.28 | 10.44 | 106.08% | |
| HCM | Hutchmed (China) Limited | 13.99 | -0.19 | -1.34% | |
| AMRX | Amneal Pharma | 21.88 | 10.36 | 90.01% | |
| TAK | Takeda Pharmaceutical Company | 21.27 | 7.21 | 51.28% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
